FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Grants Outlook Therapeutics Dispute Resolution Request

[ Price : $8.95]

FDA agrees to hear an Outlook Therapeutics formal dispute resolution request regarding the agencys prior rejection of eye disease ...

Federal Judge Pauses Challenge to Abortion Pill Rules

[ Price : $8.95]

A federal judge declines to immediately restrict access to the abortion pill mifepristone, instead pausing a high-profile lawsuit ...

Doctor Failed to Follow Investigational Plan: FDA

[ Price : $8.95]

FDA warns Newport Beach, CA-based physician Ehsan Sadri about failing to follow the investigational plan in two clinical trials.

Workshop on Improving Pregnancy Drug Safety Registries

[ Price : $8.95]

FDA plans a two-day public workshop next month aimed at improving how pregnancy registries are designed and used to assess the saf...

Organogenesis Advances ReNu Toward FDA Filing After Key Meeting

[ Price : $8.95]

Organogenesis says it has reached agreement with FDA that clears the way for a rolling BLA submission for its knee osteoarthritis ...

Support for Rare Disease Education Materials

[ Price : $8.95]

Three stakeholders express support for FDAs LEADER 3D rare disease educational materials and suggest ways to improve them.

FDA Budget Request Seeks 3% Increase

[ Price : $8.95]

FDAs just-released proposed fiscal year 2027 budget seeks a 3.3% increase or about $200 million to fund the agencys operations.

FDA Patient Preference Guide Addresses 510(k) Applicability

[ Price : $8.95]

FDAs updated guidance on how patient preference information can be incorporated into regulatory decision-making for medical device...

Positive Phase 3 Date for Subcutaneous Tepezza: Amgen

[ Price : $8.95]

Amgen reports positive topline results from a Phase 3 trial evaluating a subcutaneous version of its thyroid eye disease drug Tepe...

ImmunityBio Responds to FDA Concerns Over Promotional Materials

[ Price : $8.95]

ImmunityBio says it has responded to FDAs recent Warning Letter on the companys alleged misleading promotional claims about its ca...